Searched for
PAONTA SAHIB
Indian Technomac director held in Rs 6,000 crore fraud caseThe financial fraud, one of the biggest in the state as per records, was being investigated by the different departments of Himachal Prades...- Mankind Pharma to invest Rs 150 crore in Paonta Sahib plantThe growth of nutraceuticals market in India accounts for around 1.5 per cent of the global market which is currently estimated at $4,182 b...
- Sun Pharma in process to integrate Ranbaxy, overhauls combined global operationsThe sprawling site has been blocked by the US Food and Drug Administration since 2008 following revelations of manipulation of data.
- Daiichi to cooperate with USFDA to resolve Ranbaxy concernsDaiichi Sankyo will work with US authorities to resolve issue of a ban imposed by USFDA on import of drugs from Mohali plant of Ranbaxy.
- Certain consent decree terms to apply to Mohali unit: RanbaxyThe decree contains provisions to ensure CGMP (Current Good Manufacturing Practices) compliance at certain Ranbaxy facilities.
- Ranbaxy ignored consultants' warnings about US FDA action over malpractices, data manipulationEarlier this month Ranbaxy agreed to pay $500 mn in fines to settle data manipulation and manufacturing malpractice charges levied by the U...
- Elder Pharma to invest Rs 20 cr for cosmetics forayElder Pharmaceuticals will be investing Rs 15-20 crore over the next two-three years for its foray into cosmetics manufacturing, an officia...
- Carlsberg launches 'Carlsberg Elephant' in IndiaCarlsberg India, a unit of Denmark-based Carlsberg Group, today launched its super premium strong beer 'Carlsberg Elephant' in the Indian m...
- Ranbaxy looks to rebuild its US businessFaced with massive losses coupled with regulatory hurdles in the American market, Ranbaxy Laboratories Ltd has chalked out plans to revamp ...
- Daiichi to meet US FDA to resolve Ranbaxy issueDaiichi Sankyo, the Japanese pharmaceutical company that bought Ranbaxy Laboratories last year, will meet US FDA officials next month to so...
- Reliance Money upgrades Ranbaxy to ‘BUY’; target price Rs 189Given the attractive valuations at current levels, Reliance Money has upgraded its rating on Ranbaxy Laboratories from ‘hold’ to ‘buy’ with...
- Ranbaxy soars 10 pc on BSE; maximum single day gain this yearRanbaxy Laboratories surged over 10 per cent on the Bombay Stock Exchange, biggest single-day gain so far this year, after health regulator...
- Ranbaxy under pressure on Australia probe reportShares of Ranbaxy Laboratories dropped to a 52-week low on reports the Australian pharmaceutical regulator is investigating allegations by ...
- Aussie regulator puts Ranbaxy under scannerThe Australian drug regulator Therapeutic Goods Administration (TGA) said it is reviewing 62 drugs sold in the country which are made by Ra...
- Ranbaxy down another 4% weighed by USFDA actionShares of Ranbaxy Laboratories continued to witness fresh selling pressure on Friday. The stock was trading at Rs 164, losing another 4% in...
- Ranbaxy says to take steps to protect revenue lossIndia’s largest drug company Ranbaxy said the US drug regulator’s decision to halt approval of drugs from one of its plants in India will a...
- Ranbaxy falls 12% on USFDA regulatory actionShares of Ranbaxy Laboratories were under selling pressure, on reports of USFDA initiating new regulatory action against the company.
- US regulator charges Ranbaxy of falsifying data, test resultsTo address falsified data, FDA has invoked its Application Integrity Policy (AIP) against Paonta Sahib facility. Factors for successful M&A...
- Ranbaxy faces adulteration charges in USUS department of justice has said there was evidence to suggest that Ranbaxy used active pharmaceutical ingredients from unapproved sources...
- USFDA issues warning to RanbaxyThe USFDA has issued a warning letter to domestic pharma major Ranbaxy for deviations from good manufacturing practices at its Paonta Sahib...
Load More
